Since protein acetylation can be influenced by methyltransferase treatment and acetylation has been reported to regulate p53, in this study, we explored whether the combination of the EZH2 inhibitor Valemetostat (DS) with the HDAC inhibitor SAHA could result in increased p53 acetylation in pancreatic cancer cells. Here, TP53 is linked to pancreatic neoplasm.